CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jul. 01, 2018	Jun. 30, 2019	Jul. 01, 2018
Income Statement [Abstract]
Revenues	[1]	$ 13,264	$ 13,466	$ 26,382	$ 26,373
Costs and expenses:
Cost of sales	[1],[2]	2,576	2,916	5,009	5,479
Selling, informational and administrative expenses	[1],[2]	3,511	3,542	6,850	6,954
Research and development expenses	[1],[2]	1,842	1,797	3,544	3,540
Amortization of intangible assets	[1]	1,184	1,191	2,367	2,387
Restructuring charges and certain acquisition-related costs	[1]	(115)	44	(69)	87
Other (income)/deductions––net	[1]	126	(551)	218	(728)
Income from continuing operations before provision/(benefit) for taxes on income	[1],[3]	4,141	4,527	8,463	8,654
Provision/(benefit) for taxes on income	[1]	(915)	648	(481)	1,204
Income from continuing operations	[1]	5,056	3,879	8,945	7,450
Discontinued operations––net of tax	[1]	0	0	0	(1)
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	5,056	3,879	8,945	7,449
Less: Net income attributable to noncontrolling interests	[1]	10	7	15	16
Net income attributable to Pfizer Inc.	[1]	$ 5,046	$ 3,872	$ 8,929	$ 7,432
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.91	$ 0.66	$ 1.59	$ 1.26
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.91	0.66	1.59	1.26
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.89	0.65	1.56	1.24
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.89	$ 0.65	$ 1.56	$ 1.24
Weighted-average shares––basic	[1]	5,562	5,866	5,598	5,911
Weighted-average shares––diluted	[1]	5,672	5,952	5,711	6,004

[1] Amounts may not add due to rounding.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[3] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income of $76 million in the second quarter of 2019 and $76 million in the second quarter of 2018, and $140 million in the first six months of 2019 and $135 million in the first six months of 2018 from our investment in ViiV. For additional information, see Note 4.

[4] Amounts may not add due to rounding.

[5] Amounts may not add due to rounding.

[6] Amounts may not add due to rounding.